Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.55 |
| ▸ | CMA1 | P23946 | 5/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | CTRC | Q99895 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38652097 | 0.94 | CMA1 (0.56) | ACECMA1CTSLFKBP1AKLK5 | |
| SCHEMBL38652049 | 0.92 | ACE (0.54) | ACECMA1CTSLFKBP1AKLK5 | |
| SCHEMBL8364102 | 0.91 | ACE (0.54) | ACECMA1CTSLFKBP1AKLK5 | |
| SCHEMBL25133623 | 0.89 | KLK5 (0.55) | ACECMA1CTSLFKBP1AKLK5 | |
| SCHEMBL30859278 | 0.89 | KLK5 (0.55) | ACECMA1CTSLFKBP1AKLK5 | |
| SCHEMBL10403794 | 0.89 | ACE (0.56) | ACECMA1CTSLFKBP1AKLK5 | |
| SCHEMBL7537159 | 0.89 | ACE (0.63) | ACECMA1CTSLFKBP1AKLK5 | |
| SCHEMBL7148899 | 0.89 | ACE (0.63) | ACECMA1CTSLFKBP1AKLK5 | |
| SCHEMBL10403621 | 0.89 | KLK7 (0.53) | ACECMA1CTSLFKBP1AKLK5 | |
| SCHEMBL13413295 | 0.88 | MAPK1 (0.55) | ACECMA1CTSLFKBP1AKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708366-B2 | Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LTD. (NZ) | 2017-07-18 | — | — | US | disclosed |
| US-9212204-B2 | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-12-15 | — | — | US | disclosed |
| US-20150224164-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACID | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-08-13 | — | — | US | disclosed |
| US-20150197543-A1 | Treatment of Autism Spectrum Disorders Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-07-16 | — | — | US | disclosed |
| US-20140147491-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (AU) | 2014-05-29 | — | — | US | disclosed |
| US-8637567-B2 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid | NEUREN PHARMACEUTICALS LTD. (NZ) | 2014-01-28 | — | — | US | disclosed |
| US-20110112033-A1 | COGNITIVE ENHANCEMENT AND COGNITIVE THERAPY USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-05-12 | — | — | US | disclosed |
| US-7714020-B2 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2010-05-11 | — | — | US | disclosed |
| US-7605177-B2 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NL) | 2009-10-20 | — | — | US | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | GRM2, GRM1, GLUL | ACE 4257/4885CMA1 3418/4885CTSL 477/4885 |
| US-20140147491-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | GRIN2D, GRM2, GRIN2A | ACE 2346/4885CMA1 3421/4885CTSL 2932/4885 |
| US-20150197543-A1 | Treatment of Autism Spectrum Disorders Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid | GRIN2D, GRM2, GRIN2A | ACE 2241/4885CMA1 3315/4885CTSL 3136/4885 |
| US-20150224164-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACID | GRIN2D, GRM2, GRIK5 | ACE 2551/4885CMA1 3445/4885CTSL 3442/4885 |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | GRM2, GRIN2C, GRIN2A | ACE 4312/4885CMA1 3281/4885CTSL 855/4885 |
| US-20110112033-A1 | COGNITIVE ENHANCEMENT AND COGNITIVE THERAPY USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | CHAT, GAP43, BDNF | ACE 1263/4885CMA1 1090/4885CTSL 1174/4885 |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | CHAT, GAP43, BCHE | ACE 1430/4885CMA1 1510/4885CTSL 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.